27536134|t|RBBP6: a potential biomarker of apoptosis induction in human cervical cancer cell lines
27536134|a|Overexpression of RBBP6 in cancers of the colon, lung, and esophagus makes it a potential target in anticancer therapy. This is especially important because RBBP6 associates with the tumor suppressor gene p53, the inactivation of which has been linked to over 50% of all cancer types. However, the expression of RBBP6 in cancer and its interaction with p53 are yet to be understood in order to determine whether or not RBBP6 is cancer promoting and therefore a potential biomarker. In this study, we manipulated RBBP6 expression levels followed by treatment with either camptothecin or γ-aminobutyric acid in cervical cancer cells to induce apoptosis or cell cycle arrest. We began by staining human cervical cancer tissue sections with anti-RBBP6 monoclonal antibody to evaluate the extent of expression of RBBP6 in patients ' specimens. We followed on with silencing the overexpression of RBBP6 and treatment with anticancer agents to evaluate how the specimens respond to combinational therapy. Apoptosis induction was evaluated through confocal microscope, and flow cytometry using annexin V staining, and also by checking the mitochondrial and caspase-3/7 activity. Cell cycle arrest was evaluated using flow cytometry through staining with propidium iodide. RBBP6 was highly expressed in cervical cancer tissue sections that were in stage II or III of development. Silencing RBBP6 followed by treatment with γ-aminobutyric acid and camptothecin seems to sensitize cells to apoptosis induction rather than cell cycle arrest. Overexpression of RBBP6 seems to promote S-phase in cell cycle and cell proliferation. These results predict a proliferative role of RBBP6 in cancer progression rather than as a cancer-causing gene. Furthermore, sensitization of cells to camptothecin - induced apoptosis by RBBP6 targeting suggests a promising tool for halting cervical cancer progression.
27536134	0	5	RBBP6	T028	C1419291
27536134	9	18	potential	T080	C3245505
27536134	19	28	biomarker	T201	C0005516
27536134	32	41	apoptosis	T043	C0162638
27536134	42	51	induction	T045	C0017391
27536134	55	60	human	T016	C0086418
27536134	61	81	cervical cancer cell	T191	C0742133
27536134	82	87	lines	T025	C0007600
27536134	88	102	Overexpression	T045	C0017262
27536134	106	111	RBBP6	T028	C1419291
27536134	115	135	cancers of the colon	T191	C0699790
27536134	137	141	lung	T191	C0684249
27536134	147	156	esophagus	T191	C0152018
27536134	168	177	potential	T080	C3245505
27536134	178	184	target	T169	C1521840
27536134	188	206	anticancer therapy	T061	C0920425
27536134	245	250	RBBP6	T028	C1419291
27536134	251	266	associates with	T080	C0332281
27536134	271	296	tumor suppressor gene p53	T028	C0079419
27536134	302	314	inactivation	T169	C0544461
27536134	359	371	cancer types	T191	C0006826
27536134	386	396	expression	T045	C0017262
27536134	400	405	RBBP6	T028	C1419291
27536134	409	415	cancer	T191	C0006826
27536134	424	435	interaction	T045	C0596610
27536134	441	444	p53	T028	C0079419
27536134	507	512	RBBP6	T028	C1419291
27536134	516	532	cancer promoting	T028	C0919437
27536134	549	558	potential	T080	C3245505
27536134	559	568	biomarker	T201	C0005516
27536134	578	583	study	T059	C0947630
27536134	588	599	manipulated	T061	C0947647
27536134	600	605	RBBP6	T028	C1419291
27536134	606	623	expression levels	T081	C3244092
27536134	636	645	treatment	T169	C1522326
27536134	658	670	camptothecin	T109,T121	C0006812
27536134	674	693	γ-aminobutyric acid	T116,T123	C0016904
27536134	697	718	cervical cancer cells	T191	C0742133
27536134	722	728	induce	T045	C0017391
27536134	729	738	apoptosis	T043	C0162638
27536134	742	759	cell cycle arrest	T043	C1155873
27536134	773	781	staining	T059	C0487602
27536134	782	787	human	T016	C0086418
27536134	788	819	cervical cancer tissue sections	T191	C0742133
27536134	836	855	monoclonal antibody	T116,T129	C0003250
27536134	859	867	evaluate	T058	C0220825
27536134	882	892	expression	T045	C0017262
27536134	896	901	RBBP6	T028	C1419291
27536134	905	913	patients	T101	C0030705
27536134	916	925	specimens	T077	C2347026
27536134	947	956	silencing	T045	C0598496
27536134	961	975	overexpression	T045	C0017262
27536134	979	984	RBBP6	T028	C1419291
27536134	989	998	treatment	T169	C1522326
27536134	1004	1021	anticancer agents	T109,T121	C0003392
27536134	1025	1033	evaluate	T058	C0220825
27536134	1042	1051	specimens	T077	C2347026
27536134	1063	1076	combinational	T080	C0205195
27536134	1077	1084	therapy	T061	C0087111
27536134	1086	1095	Apoptosis	T043	C0162638
27536134	1096	1105	induction	T045	C0017391
27536134	1110	1119	evaluated	T058	C0220825
27536134	1128	1147	confocal microscope	T074	C1626420
27536134	1153	1167	flow cytometry	T059	C0016263
27536134	1174	1183	annexin V	T116,T123	C0059249
27536134	1184	1192	staining	T059	C0487602
27536134	1206	1214	checking	T052	C1283174
27536134	1219	1232	mitochondrial	T026	C0026237
27536134	1237	1257	caspase-3/7 activity	T044	C1150130
27536134	1259	1276	Cell cycle arrest	T043	C1155873
27536134	1281	1290	evaluated	T058	C0220825
27536134	1297	1311	flow cytometry	T059	C0016263
27536134	1320	1328	staining	T059	C0487602
27536134	1334	1350	propidium iodide	T109,T130	C0033470
27536134	1352	1357	RBBP6	T028	C1419291
27536134	1362	1368	highly	T080	C0205250
27536134	1369	1378	expressed	T045	C0017262
27536134	1382	1413	cervical cancer tissue sections	T191	C0742133
27536134	1427	1435	stage II	T170	C0441767
27536134	1439	1457	III of development	T170	C0441771
27536134	1459	1468	Silencing	T045	C0598496
27536134	1469	1474	RBBP6	T028	C1419291
27536134	1487	1496	treatment	T169	C1522326
27536134	1502	1521	γ-aminobutyric acid	T116,T123	C0016904
27536134	1526	1538	camptothecin	T109,T121	C0006812
27536134	1548	1563	sensitize cells	T025	C0312864
27536134	1567	1576	apoptosis	T043	C0162638
27536134	1577	1586	induction	T045	C0017391
27536134	1599	1616	cell cycle arrest	T043	C1155873
27536134	1618	1632	Overexpression	T045	C0017262
27536134	1636	1641	RBBP6	T028	C1419291
27536134	1651	1658	promote	T052	C0033414
27536134	1659	1666	S-phase	T079	C0080129
27536134	1670	1680	cell cycle	T043	C0007586
27536134	1685	1703	cell proliferation	T043	C0596290
27536134	1711	1718	results	T033	C2825142
27536134	1751	1756	RBBP6	T028	C1419291
27536134	1760	1778	cancer progression	T046	C1947901
27536134	1796	1815	cancer-causing gene	T028	C0029016
27536134	1830	1843	sensitization	T040	C1325847
27536134	1847	1852	cells	T025	C0007634
27536134	1856	1868	camptothecin	T109,T121	C0006812
27536134	1871	1878	induced	T046	C0007994
27536134	1879	1888	apoptosis	T043	C0162638
27536134	1892	1897	RBBP6	T028	C1419291
27536134	1898	1907	targeting	T063	C0242613
27536134	1938	1945	halting	T052	C1947925
27536134	1946	1973	cervical cancer progression	T046	C1947901